TP53 and neoplasm: Wilkinson et al. identified TP53 alterations, PTEN loss, nuclear ERG expression, tumor volume, and IDC-P as potential predictors of response to androgen deprivation therapy, with an area under the curve of 0.98 [24]; this implies a potential role for IDC-P as a biomarker for treatment efficacy.